
Opinion|Videos|March 11, 2024
MIRASOL trial and DESTINY-PanTumor02 Trial Overview
Ronald D. Alvarez, MD, MBA, gives an analysis of the MIRASOL and DESTINY-PanTumor02 trials, including a comparison of study arms and discussion of HER2/neu targeting.
Advertisement
Episodes in this series

Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
HERIZON-GEA-01 Results Indicate Potential 1L Use of Zanidatamab for Gastroesophageal Adenocarcinoma
2
USDA and HHS Update Dietary Guidelines to Encourage Real Food, Less Sugar
3
Social Determinants of Health Linked to Worse Outcomes in Hypertrophic Cardiomyopathy
4
CDC Vaccine Rollback Highlights Gaps in Public Understanding of Shared Decision-Making
5






























































